TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33221898
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of antimicrobial prescription rates
Study: 34417443
Drug: Testosterone (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (0.50 mg)
Study: 32049889
Drug: Intravenous tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous tobramycin at 8:00 hours
Study: 32049889
Drug: Intravenous tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous tobramycin at 22:00 hours
Study: 33600729
Drug: Short-acting bronchodilators
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting bronchodilators
Study: 37936408
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid (ICS) therapy
Study: 33561426
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone 4 mg administered preemptively
Study: 34786952
Drug: Pulsed radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed radiofrequency treatment (PRF) with pregabalin
Study: 34399547
Drug: L-cysteine hydrochloride;
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-cysteine hydrochloride; concentration 4.23 mM at pH 8.71
Study: 35686393
Drug: Technology-enhanced physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technology-enhanced physical activity intervention (bi-weekly education sessions for 4 weeks, monthly small group walks for 8 weeks, weekly reminder text messages)
Study: 32921337
Drug: Lurasidone (40‐160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (40‐160 mg/d)
Study: 36261491
Drug: Gel group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel group (poloxamer 407‐based 0.75% ropivacaine, 22.5 mg)
Study: 36261491
Drug: On-Q group
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-Q group (0.2% ropivacaine, 4 mg/hour for two days)
Study: 36261491
Drug: Gel group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel group
Study: 35927674
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of 10^7 umbilical cord-derived Wharton's jelly mesenchymal stem cells (WJ-MSCs)
Study: 35582785
Drug: Dextromethorphan-bupropion (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan-bupropion (45 mg/105 mg tablet)
Study: 35582785
Drug: Bupropion (105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (105 mg tablet)
Study: 33864432
Drug: Standard tuberculosis
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard tuberculosis therapy alone
Study: 37165291
Drug: Rasburicase 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasburicase 0.20 mg/kg/day
Study: 32988969
Drug: Exemestane 50
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane 50 mg with enzalutamide 160 mg daily
Study: 32988969
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg with placebo
Study: 36397443
Drug: Family-involved smart
Normalized name: benzalkonium chloride Topical Foam [Smart San]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-involved smart medication management system
Study: 36397443
Drug: Routine medication
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medication management model
Study: 35568805
Drug: Tablet-based physiotherapy
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based physiotherapy training programme at home for nine months
Study: 37579773
Drug: MenABCWY vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenABCWY vaccine
Study: 33983107
Drug: Wheat germ
Normalized name: Wheat Germ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat germ (20 g)
Study: 34337526
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg high-dose estetrol (HDE4) for 24 weeks
Study: 33206257
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (PA)
Study: 33206257
Drug: Immunoglobulin replacement
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin replacement therapy (IRT)
Study: 34261076
Drug: PRP subcutaneous
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP subcutaneous injection
Study: 35894919
Drug: Supervised concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised concurrent (aerobic + resistance) exercise program, 3 days/week
Study: 33428631
Drug: Over-the-counter (OTC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-the-counter (OTC) medications for CIC, including bisacodyl (33%) and polyethylene glycol (30%)
Study: 35988193
Drug: LEEP under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LEEP under propofol intravenous anesthesia combined with nano-silver gel
Study: 35988193
Drug: LEEP under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LEEP under intravenous anesthesia with fentanyl
Study: 35264362
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg iron supplementation (placebo)
Study: 35264362
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg iron supplementation
Study: 35264362
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg iron supplementation
Study: 35264362
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation daily for 56 days
Study: 32091670
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training (ST) twice a week for 10 weeks
Study: 33449326
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel pre and post flexible cystoscopy
Study: 33449326
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel pre flexible cystoscopy only
Study: 34242472
Drug: Supratherapeutic venlafaxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supratherapeutic venlafaxine 450 mg/d
Study: 34715839
Drug: 6 mL 2%‐lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mL 2%‐lidocaine intracervical block
Study: 34715839
Drug: 550 mg naproxen
Normalized name: naproxen sodium 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 mg naproxen
Study: 32421854
Drug: VT-1161 300
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VT-1161 300 mg (2-week daily dose, followed by once-weekly for 10 or 22 weeks)
Study: 32421854
Drug: VT-1161 600
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VT-1161 600 mg (2-week daily dose, followed by once-weekly for 10 or 22 weeks)
Study: 33754923
Drug: Red spinach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red spinach extract (RSE) 2g daily (180mg nitrate)
Study: 33491787
Drug: Oral potassium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral potassium and magnesium supplements administered pre-procedure based on pre-electrolyte levels.
Study: 32269534
Drug: SCIT-VR therapy
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SCIT-VR therapy delivered through the virtual world platform Second Life©, 8 sessions over a 5-week intervention window.
Study: 33413593
Drug: Restrictive Fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive Fluid Therapy combined with Enhanced Recovery After Surgery (ERAS) protocol
Study: 33731219
Drug: Physical Activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Activity on Prescription (PAP)
Study: 34542204
Drug: Spirulina-fortified dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina-fortified dressing (2 g of spirulina platensis powder)
Study: 35830312
Drug: Immediate postextraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate postextraction implants with grafting the bone‐to‐implant gap (Group A)
Study: 35830312
Drug: Delayed implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implants inserted after alveolar ridge preservation (Group B)
Study: 35712259
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump with independent intermittent scanning continuous glucose monitoring (iscCGM, Freestyle libre ®)
Study: 35712259
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment preference after one year
Study: 35108185
Drug: One-stage treatment
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage treatment protocol
Study: 35108185
Drug: Two-stage treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-stage treatment protocol
Study: 33607792
Drug: Periarticular injection
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injection (PAI) of multimodal drugs
Study: 32745667
Drug: Increased planned
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Increased planned radiotherapy dose (>55 Gy) in a small rectal volume adjacent to the clinical target volume.
Study: 32745667
Drug: Increased low-intermediate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased low-intermediate planned radiotherapy dose (∼25 Gy) at the posterior beam region, including the posterior rectum and perirectal fat space (PRFS).
Study: 35765223
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection of mecobalamin at Zusanli (S36)
Study: 35765223
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of mecobalamin
Study: 32066032
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT (66.7% tube load)
Study: 32066032
Drug: Ultralow-dose CT
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultralow-dose CT (33.3% tube load)
Study: 32066032
Drug: Standard-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CT (100% tube load)
Study: 34271984
Drug: Internet-based Emotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based Emotion Regulation Individual Therapy for Adolescents (ERITA) as an add-on to treatment as usual
Study: 33196739
Drug: 2,940 nm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,940 nm fractional erbium:YAG laser treatment
Study: 36416319
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no desensitizing treatment)
Study: 34939119
Drug: We Can
Normalized name: CAN-106
DrugBank: CAN-106 (DB18389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: We Can Quit (group support + nicotine replacement therapy)
Study: 34145727
Drug: Duloxetine 30
Normalized name: duloxetine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 30 mg orally (group D)
Study: 34145727
Drug: Starch placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch placebo capsules (group C)
Study: 37891566
Drug: Non-adherence to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adherence to medication
Study: 35512259
Drug: 3-month treatment
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month treatment group (FOLFOX or CAPOX)
Study: 35512259
Drug: 6-month treatment
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month treatment group (FOLFOX or CAPOX)
Study: 36258848
Drug: Pregabalin 300
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300 mg before anesthesia
Study: 36258848
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules before anesthesia and intravenous Mg sulfate 30 mg/kg during the perioperative period
Study: 36258848
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules before anesthesia and normal intravenous saline during the operation
Study: 34610178
Drug: Viburnum opulus
Normalized name: Viburnum opulus root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viburnum opulus 1000 mg peroral 3 × 2 and diclofenac 50 mg peroral on-demand
Study: 34610178
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg peroral 1 × 1 and diclofenac 50 mg peroral on-demand
Study: 34784991
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy intervention (Recovery through Group Study - ReGroup)
Study: 34548367
Drug: Weekly injections
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly injections of 250 mg 17-hydroxyprogesterone caproate
Study: 35621073
Drug: Nano-curcumin (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nano-curcumin (160 mg) administered via nasogastric tube twice a day for 10 days
Study: 35621073
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via nasogastric tube twice a day for 10 days
Study: 32320797
Drug: Tiotropium Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium Respimat 5 μg once daily added to high-dose ICS plus long-acting β2-agonist (severe asthma)
Study: 32320797
Drug: Tiotropium Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium Respimat 2.5 or 5 μg once daily added to medium-dose ICS (moderate asthma)
Study: 32929910
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid sequential rivaroxaban
Study: 34292336
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate with prednisone plus bone resorption inhibitors (BRIs)
Study: 35880279
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (30 min, 3 times per week for 12 weeks) at acupoints including Baihui (GV20), Zhongwan (CV12), Shenting (GV24), Shenshu (BL23), Ciliao (BL32)
Study: 32597548
Drug: Intensified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified treatment (IT)
Study: 33999548
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg of aspirin per day
Study: 33999548
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg of aspirin per day
Study: 33077258
Drug: Oral nintedanib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nintedanib (BIBF 1120) with oral cyclophosphamide (100 mg o.d.)
Study: 33077258
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with oral cyclophosphamide (100 mg o.d.)
Study: 35794067
Drug: OPC-61815 (16-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-61815 (16-mg injection)
Study: 35794067
Drug: Oral tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral tolvaptan (15-mg tablet)
Study: 33548206
Drug: Platelet-Rich Plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-Rich Plasma (PRP) injection (3.5mL)
Study: 33548206
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injection (3.5mL)
Study: 32495521
Drug: Experiment group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experiment group (n = 62) received 600 mg/d of calcium carbonate, 0.5 μg/d of alfacalcidol, and 70 mg/week of alendronate for 18 months
Study: 32495521
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 61) received 600 mg/d of calcium carbonate and 0.5 μg/d of alfacalcidol for 18 months
Study: 33715258
Drug: 1.2% simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2% simvastatin (SIM) gel covered with polypropylene membranes (PPPM)
Study: 33715258
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel covered with polypropylene membranes (PPPM)
Study: 32571889
Drug: Dual thromboprophylaxis
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual thromboprophylaxis (mechanical thromboprophylaxis with sequential compression devices and 28-day prophylaxis with low molecular weight heparin)
Study: 32571889
Drug: Pre-intervention (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-intervention (low molecular weight heparin during admission and extended 28-day prophylaxis at surgeon's discretion)
Study: 36225172
Drug: EBV‐miR‐BART5‐3p inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBV‐miR‐BART5‐3p inhibitor
Study: 36225172
Drug: EBV‐miR‐BART5‐3p inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBV‐miR‐BART5‐3p inhibitors
Study: 32878708
Drug: TAK-214 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-214 (15 μg GI.1 and 50 μg GII.4c VLPs, 0.5 mg Al(OH)3)
Study: 35073324
Drug: Diagnostic dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic dose bioassays using permethrin
Study: 35551341
Drug: RD43 rice
Normalized name: RICE
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RD43 rice (Glycemic Index [GI] = 78) containing 14.1 g of undigestible starch daily as a substitute for two meals per day
Study: 34115148
Drug: Hyperglycaemia (17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemia (17 mmol/l) with 5 mU [m2 BSA]−1 min−1 insulin
Study: 34609548
Drug: Standardized oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized oral care bundle
Study: 32534578
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg ipragliflozin daily
Study: 32534578
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of background treatment (non-SGLT2i)
Study: 35883392
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of microfragmented adipose tissue
Study: 32800303
Drug: Internet-based cognitive-behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavior treatment (CBT)
Study: 32147072
Drug: 2.25 g
Normalized name: Zosyn 2.25 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.25 g ginsenoside Rg3-enriched KRG & AG co-administration
Study: 32646502
Drug: Standard outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard outpatient treatment plus prednisone (60 mg/24 h for 3 days, 30 mg/24 h for 3 days, and 15 mg/24 h for 3 days)
Study: 32646502
Drug: Standard outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard outpatient treatment only (paracetamol 1 g/8 h on demand + hydroxychloroquine 400 mg/12h first day, 200 mg/12 h for 4 days + azithromycin 500 mg/24h for 5 days)
Study: 32646502
Drug: Standard outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard outpatient treatment plus prednisone
Study: 35166922
Drug: Subcutaneous rHuEPO
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rHuEPO 50 U/kg three times weekly until discharge
Study: 35166922
Drug: RBC transfusion
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC transfusion if hemoglobin ≤ 7 g/dL and/or hemodynamic instability
Study: 32673006
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure therapy (COPE)
Study: 34866234
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous vitamin C (2.5 g/6 h for 96 hours)
Study: 36894736
Drug: Women using
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women using oral contraceptives (n = 9 in Stress, n = 10 in No-Stress)
Study: 33660906
Drug: Integrative Cognitive‐Affective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Cognitive‐Affective Therapy
Study: 33660906
Drug: Cognitive‐behavioural therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioural therapy administered using guided self‐help
Study: 32989046
Drug: Supraglottic airway
Normalized name: inBreath airway transplant system
DrugBank: inBreath airway transplant system (DB18692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraglottic airway device for surfactant administration
Study: 32989046
Drug: Surfactant administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant administration via endotracheal tube
Study: 32397980
Drug: Myrrh (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myrrh (500 mg capsules, three times a day for 2 weeks)
Study: 35182247
Drug: Nivolumab (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (360 mg every 3 weeks) plus ipilimumab (1 mg/kg every 6 weeks) combined with chemotherapy (2 cycles, every 3 weeks)
Study: 35182247
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab combined with chemotherapy
Study: 34328501
Drug: Guided internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet-delivered cognitive behavioral therapy
Study: 34328501
Drug: In-person cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-person cognitive behavioral therapy
Study: 34328501
Drug: Stepped-care group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped-care group (internet-delivered therapy followed by in-person for nonresponders)
Study: 34328501
Drug: In-person cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-person cognitive behavioral therapy alone